Related Experiment Video

Updated: May 21, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents

David A Burke1, Haider J Warraich, Duane S Pinto

  • 1Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA.

Current Cardiology Reports
|June 5, 2012
PubMed

Insights

Anticoagulation is vital for acute coronary syndromes (ACS). Novel agents targeting Factor Xa or thrombin offer improved clinical benefits while minimizing bleeding risks in various heart conditions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Anticoagulation is a cornerstone in managing acute coronary syndromes (ACS).
  • Current anticoagulation strategies aim to balance anti-ischemic benefits with bleeding risks.
  • Thrombus development involves complex pathways including thrombin formation and platelet activation.

Purpose of the Study:

  • To review the role of novel anticoagulants in ACS management.
  • To evaluate the efficacy and safety of agents targeting Factor Xa and thrombin.
  • To assess the net clinical benefit of these agents across different cardiovascular conditions.

Main Methods:

  • Review of existing data and clinical studies on novel anticoagulants.
  • Analysis of pharmacological mechanisms of action for Factor Xa and thrombin inhibitors.
  • Evaluation of clinical outcomes including ischemic events and bleeding complications.

Main Results:

  • Novel anticoagulants targeting Factor Xa or thrombin demonstrate significant clinical benefits.
  • These agents effectively reduce thrombus development by inhibiting key coagulation factors.
  • Data indicate a favorable net clinical benefit in patients with stable ischemic heart disease, unstable angina, NSTEMI, and STEMI.

Conclusions:

  • Novel anticoagulants represent a significant advancement in ACS treatment.
  • Targeting specific coagulation factors offers a more precise approach to anticoagulation.
  • These agents provide a favorable risk-benefit profile for a broad range of cardiovascular patients.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...